Clinical and pathological implications of miRNA in bladder cancer

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 791-800

  Braicu, Cornelia ^a   Cojocneanu Petric, Roxana ^a,b   Chira, Sergiu ^a   Truta, Anamaria ^a   Floare, Alexandru ^c   Petrut, Bogdan ^a,d   Achimas Cadariu, Patriciu ^a,d   Berindan Neagoe, Ioana ^a,d,e  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b BABE BOLYAI UNIVERSITY   (Romania)

^c Solutions of Artificial Intelligence Applications   (Romania)

^d THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bladder cancer; Diagnostic; MiRNA; Prognostic

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 124; MICRORNA 183 96 182; MICRORNA 200; MICRORNA 205; MICRORNA 21; MICRORNA 210; MICRORNA 214; MICRORNA 23B; MICRORNA 29C; MICRORNA 409; MICRORNA 590 3P; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CANCER PROGNOSIS; CARCINOGENESIS; CELL COMMUNICATION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; GENE TARGETING; HUMAN; NONHUMAN; PROSTATE ADENOCARCINOMA; BLADDER TUMOR; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY;

GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; URINARY BLADDER NEOPLASMS;

EID: 84921863691     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/ijn.s72904     Document Type: Article

References (51)

1. Urquidi V, Rosser CJ, Goodison S. Molecular diagnostic trends in urological cancer: biomarkers for non-invasive diagnosis. Curr Med Chem. 2012;19(22):3653–3663.
2. International Agency for Research on Cancer and the World Health Organization. The GLOBOCAN Project. Available from: http://globocan.iarc.fr/. Accessed December 5, 2014.
3. National Cancer Institute. Surveillance Research Program. Bethesda, MD: National Cancer Institute. Available from: http://surveillance.cancer.gov/.Accessed December 5, 2014.
4. American Cancer Society. Cancer Facts and Figures2013. Atlanta: American Cancer Society; 2013.
5. Ratert N, Meyer HA, Jung M, et al. miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. J Mol Diagn. 2013;15(5):695–705.
6. Rosenberg E, Baniel J, Spector Y, et al. Predicting progression of bladder urothelial carcinoma using microRNA expression. BJU Int. 2013;112(7):1027–1034.
7. Majid S, Saini S, Dahiya R. Wnt signaling pathways in urological cancers: past decades and still growing. Mol Cancer. 2012;11(1):7.
8. Heneghan HM, Miller N, Kerin MJ. MiRNAs as biomarkers and therapeutic targets in cancer. Curr Opin Pharmacol. 2010;10(5):543–550.
9. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10(10):704–714.
10. Huang S, He X. The role of microRNAs in liver cancer progression. Br J Cancer. 2011;104(2):235–240.
11. Wang D, Qiu C, Zhang H, Wang J, Cui Q, Yin Y. Human microRNA oncogenes and tumor suppressors show significantly different biological patterns: from functions to targets. PLoS One. 2010;5(9):e13067.
12. Hu Z, Lin Y, Chen H, et al. MicroRNA-101 suppresses motility of bladder cancer cells by targeting c-Met. Biochem Biophys Res Commun. 2013;435(1):82–87.
13. Xu X, Li S, Lin Y, et al. MicroRNA-124-3p inhibits cell migration and invasion in bladder cancer cells by targeting ROCK1. J Transl Med. 2013;11(1):276.
14. Pignot G, Cizeron-Clairac G, Vacher S, et al. microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer. Int J Cancer. 2013;132(11):2479–2491.
15. Han Y, Chen J, Zhao X, et al. MicroRNA expression signatures of bladder cancer revealed by deep sequencing. PLoS ONE. 2011;6(3):e18286.
16. Adam L, Wszolek MF, Liu CG, et al. Plasma microRNA profiles for bladder cancer detection. Urol Oncol. 2013;31(8):1701–1708.
17. Xu X, Chen H, Lin Y, et al. MicroRNA-409-3p inhibits migration and invasion of bladder cancer cells via targeting c-Met. Mol Cells. 2013;36(1):62–68.
18. Schaefer A, Jung M, Mollenkopf HJ, et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 2010;126(5):1166–1176.
19. Wotschofsky Z, Liep J, Meyer HA, et al. Identification of metastamirs as metastasis-associated microRNAs in clear cell renal cell carcinomas. Int J Biol Sci. 2012;8(10):1363–1374.
20. Li S, Xu X, Xu X, et al. MicroRNA-490-5p inhibits proliferation of bladder cancer by targeting c-Fos. Biochem Biophys Res Commun. 2013;441(4):976–981.
21. Kim SM, Kang HW, Kim WT, et al. Cell-Free microRNA-214 From Urine as a Biomarker for Non-Muscle-Invasive Bladder Cancer. Korean J Urol. 2013;54(11):791–796.
22. Wang G, Chan ES, Kwan BC, et al. Expression of microRNAs in the urine of patients with bladder cancer. Clin Genitourin Cancer. 2012;10(2):106–113.
23. Majid S, Dar AA, Saini S, et al. MicroRNA-23b functions as a tumor suppressor by regulating Zeb1 in bladder cancer. PLoS ONE. 2013;8(7):e67686.
24. Wiklund ED, Bramsen JB, Hulf T, et al. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer. 2011;128(6):1327–1334.
25. Wiklund ED, Bramsen JB, Hulf T, et al. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer. 2011;128(6):1327–1334.
26. Shimizu T, Suzuki H, Nojima M, et al. Methylation of a panel of microRNA genes is a novel biomarker for detection of bladder cancer. Eur Urol. 2013;63(6):1091–1100.
27. Pignot G, Cizeron-Clairac G, Vacher S, et al. microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer. Int J Cancer. 2013;132(11):2479–2491.
28. Wang S, Xue S, Dai Y, et al. Reduced expression of microRNA-100 confers unfavorable prognosis in patients with bladder cancer. Diagn Pathol. 2012;7:159.
29. Lee H, Jun SY, Lee YS, Lee HJ, Lee WS, Park CS. Expression of miRNAs and ZEB1 and ZEB2 correlates with histopathological grade in papillary urothelial tumors of the urinary bladder. Virchows Arch. 2013.
30. Catto JW, Miah S, Owen HC, et al. Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res. 2009;69(21):8472–8481.
31. Guancial EA, Bellmunt J, Yeh S, Rosenberg JE, Berman DM. The evolving understanding of microRNA in bladder cancer. Urol Oncol. 2014;32(1):41.e31–e40.
32. Junker K, van Oers JM, Zwarthoff EC, Kania I, Schubert J, Hartmann A. Fibroblast growth factor receptor 3 mutations in bladder tumors correlate with low frequency of chromosome alterations. Neoplasia. 2008;10(1):1–7.
33. Zabolotneva AA, Zhavoronkov AA, Shegay PV, et al. A systematic experimental evaluation of microRNA markers of human bladder cancer. Front Genet. 2013;4:247.
34. Liu Y, Han Y, Zhang H, et al. Synthetic miRNA-mowers targeting miR-183-96-182 cluster or miR-210 inhibit growth and migration and induce apoptosis in bladder cancer cells. PLoS ONE. 2012;7(12):e52280.
35. Yang W, Sun T, Cao J, Liu F, Tian Y, Zhu W. Downregulation of miR-210 expression inhibits proliferation, induces apoptosis and enhances radiosensitivity in hypoxic human hepatoma cells in vitro. Exp Cell Res. 2012;318(8):944–954.
36. Mo M, Peng F, Wang L, Peng L, Lan G, Yu S. Roles of mitochondrial transcription factor A and microRNA-590-3p in the development of bladder cancer. Oncol Lett. 2013;6(2):617–623.
37. Adam L, Zhong M, Choi W, et al. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res. 2009;15(16):5060–5072.
38. Kozinn SI, Harty NJ, Delong JM, et al. MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines. Genes Cancer. 2013;4(1–2):61–69.
39. Drayton RM, Dudziec E, Peter S, et al. Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11. Clin Cancer Res. 2014;20(7):1990–2000.
40. Jia AY, Castillo-Martin M, Bonal DM, Sánchez-Carbayo M, Silva JM, Cordon-Cardo C. MicroRNA-126 inhibits invasion in bladder cancer via regulation of ADAM9. Br J Cancer. 2014;110(12):2945–2954.
41. Majid S, Dar AA, Saini S, et al. MicroRNA-1280 inhibits invasion and metastasis by targeting ROCK1 in bladder cancer. PLoS ONE. 2012;7(10):e46743.
42. Itesako T, Seki N, Yoshino H, et al. The microRNA expression signature of bladder cancer by deep sequencing: the functional significance of the miR-195/497 cluster. PLoS One. 2014;9(2):e84311.
43. Uchino K, Takeshita F, Takahashi RU, et al. Therapeutic effects of microRNA-582-5p and -3p on the inhibition of bladder cancer progression. Mol Ther. 2013;21(3):610–619.
44. Jeffrey SS. Cancer biomarker profiling with microRNAs. Nat Biotechnol. 2008;26(4):400–401.
45. Weber JA, Baxter DH, Zhang S, et al. The microRNA spectrum in 12 body fluids. Clin Chem. 2010;56(11):1733–1741.
46. Wadhwa N, Jatawa SK, Tiwari A. Non-invasive urine based tests for the detection of bladder cancer. J Clin Pathol. 2012;65(11):970–975.
47. Rosenberg E, Baniel J, Spector Y, et al. Predicting progression of bladder urothelial carcinoma using microRNA expression. BJU Int. 2013;112(7):1027–1034.
48. Puerta-Gil P, García-Baquero R, Jia AY, et al. miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. Am J Pathol. 2012;180(5):1808–1815.
49. Hanke M, Hoefig K, Merz H, et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol. 2010;28(6):655–661.
50. Tölle A, Jung M, Rabenhorst S, Kilic E, Jung K, Weikert S. Identification of microRNAs in blood and urine as tumour markers for the detection of urinary bladder cancer. Oncol Rep. 2013;30(4):1949–1956.
51. Yamada Y, Enokida H, Kojima S, et al. MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Sci. 2011;102(3):522–529.